1. Home
  2. ALDX vs ATNI Comparison

ALDX vs ATNI Comparison

Compare ALDX & ATNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALDX
  • ATNI
  • Stock Information
  • Founded
  • ALDX 2004
  • ATNI 1987
  • Country
  • ALDX United States
  • ATNI United States
  • Employees
  • ALDX N/A
  • ATNI N/A
  • Industry
  • ALDX Biotechnology: Pharmaceutical Preparations
  • ATNI Telecommunications Equipment
  • Sector
  • ALDX Health Care
  • ATNI Telecommunications
  • Exchange
  • ALDX Nasdaq
  • ATNI Nasdaq
  • Market Cap
  • ALDX 342.3M
  • ATNI 254.3M
  • IPO Year
  • ALDX 2014
  • ATNI 1991
  • Fundamental
  • Price
  • ALDX $5.39
  • ATNI $15.83
  • Analyst Decision
  • ALDX Strong Buy
  • ATNI Strong Buy
  • Analyst Count
  • ALDX 2
  • ATNI 1
  • Target Price
  • ALDX $9.50
  • ATNI $30.00
  • AVG Volume (30 Days)
  • ALDX 776.7K
  • ATNI 35.2K
  • Earning Date
  • ALDX 11-06-2025
  • ATNI 10-28-2025
  • Dividend Yield
  • ALDX N/A
  • ATNI 7.06%
  • EPS Growth
  • ALDX N/A
  • ATNI N/A
  • EPS
  • ALDX N/A
  • ATNI N/A
  • Revenue
  • ALDX N/A
  • ATNI $719,593,000.00
  • Revenue This Year
  • ALDX N/A
  • ATNI $1.60
  • Revenue Next Year
  • ALDX $63.48
  • ATNI $1.38
  • P/E Ratio
  • ALDX N/A
  • ATNI N/A
  • Revenue Growth
  • ALDX N/A
  • ATNI N/A
  • 52 Week Low
  • ALDX $1.14
  • ATNI $13.76
  • 52 Week High
  • ALDX $7.20
  • ATNI $33.72
  • Technical
  • Relative Strength Index (RSI)
  • ALDX 45.97
  • ATNI 47.65
  • Support Level
  • ALDX $5.48
  • ATNI $15.22
  • Resistance Level
  • ALDX $5.88
  • ATNI $17.01
  • Average True Range (ATR)
  • ALDX 0.26
  • ATNI 0.95
  • MACD
  • ALDX -0.08
  • ATNI 0.01
  • Stochastic Oscillator
  • ALDX 2.33
  • ATNI 32.68

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

About ATNI ATN International Inc.

ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.

Share on Social Networks: